ecrin-mdr-crcClinical2019IPD Sharing (as of July 2019): NoMetastatic Colorectal CancerColorectal NeoplasmsMetastatic Colorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2310049China7Second lineXELOXRegorafenibOxaliplatinCapecitabineECRIN MDRNot yet recruitingfalseRegorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal CancerThis is an interventional, randomized open-label, parallel-group, multicenter, dose escalation phase Ib/II study, to investigate the combination of Regorafenib and XELOX as 2nd line treatment in mCRC patients.2019-07-152310049NCT04008511